Back to search

Peptide record

TPDB91828

Pen Penetratin PN58 (SEQ ID NO: 53) Antibacterial Anticancer Antifungal Antiviral Blood-Brain Barrier Cell-penetrating Peptides Toxicity standard
16 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB91828
Pen Penetratin PN58 (SEQ ID NO: 53)
Antibacterial Anticancer Antifungal Antiviral Blood-Brain Barrier Cell-penetrating Peptides Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides Delivery and barrier-penetrating peptides
AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 iACP-DRLF pep-lab Antifungipept CAFPdb AI4AVP B3Pred BBPpredict CellPPD CellPPD-MOD CPPsite3.0 PerseuCPP
standard
No
A 16-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
RQIKIWFQNRRMKWKK-NH2
Physicochemical Analysis
C104H168N34O20S1
ADCEGHLPSTYV
K
2246.75
12.72
7
0
6
+7
2.29
-1.731
48.75
Mammalian: 1 hour Yeast: 2 min E.coli: 2 min
11000
489.60
3
Residue Composition
number
0
A
3
R
1
N
0
D
0
C
0
E
2
Q
0
G
0
H
2
I
0
L
4
K
1
M
1
F
0
P
0
S
0
T
2
W
0
Y
0
V
Amino Acid Distribution
A: 0 R: 3 N: 1 D: 0 C: 0 E: 0 Q: 2 G: 0 H: 0 I: 2 L: 0 K: 4 M: 1 F: 1 P: 0 S: 0 T: 0 W: 2 Y: 0 V: 0
Chemical Descriptors
16
C104H168N34O20S1
2246.75
12.72
+7
2.29
-1.731
Amidation
L
Cationic and amphipathic Cationic Amphipathic
Linear Tetramer
Free
N[C@@H](CCCN=C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N1CCC[C@H]1C(=O)O N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)O N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCCN)C(=O)O N[C@@H](CCCN=C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O N[C@@H](CCCN=C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCN=C)C(=O)O NCC(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)N)C(=O)O
Evidence Records 10 records
Evidence 1 Activity

Activity

Cell-penetrating Peptides

Target

9 L/LacZ cells

Source & Reference

CPPsite3.0
CPPsite3
US 20060035815

Other

Source Activity Label Source Definition
Cell-penetrating Peptides
CPPsite3.0 experimentally validated cell-penetrating peptide annotation.
Natural residues Linear L
Synthetic
Nucleic acid (siRNA)
In vitro
CCCSSSTTCCCTTTTC
Evidence 2 Activity

Activity

Cell-penetrating Peptides

Target

Swiss 3T3 cells and bovine spermatozoa

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L Cationic and amphipathic
Protein derived
Fluorophore (TAMRA)
Direct Translocation
In vitro
CCCSSSTTCCCTTTTC
Evidence 3 Activity

Activity

Cell-penetrating Peptides

Target

HeLa cells

Source & Reference

CPPsite3.0
CPPsite3
US 2014/0140929 A1

Other

Natural residues Linear L Cationic and amphipathic
Protein derived
Nucleic acid (SCO)
Endocytosis
In vitro
CCCSSSTTCCCTTTTC
Evidence 4 Activity

Activity

Cell-penetrating Peptides

Target

HeLa Wt Cells

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L
Protein derived
Selenium uptake was significantly higher for the TAMRA labelled peptides compared to Se-labelled Pen.
In vitro
CCCSSSTTCCCTTTTC
Evidence 5 Activity

Activity

Cell-penetrating Peptides

Target

HeLa Cells, MDA-MB-231 And Skbr-3 Cell Lines

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L
Protein derived
G7-18NATE, G7-M2 , G7-B7 and G7-B7M2
Cytosol
The mono-cyclic G7-peptides (G7-18NATE-Pen and G7-M2-Pen) are clearly superior in cellular uptake than the bicyclic peptides (G7-B7-Pen and/or G7-B7M2-Pen) while G7-18NATE without Pen does not internalize inside cells.
In vitro
CCCCCCCCCCCCSCC
Evidence 6 Activity

Activity

Cell-penetrating Peptides

Target

Rbl-2H3 Cells

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L Cationic
Protein derived
TAMRA dye
Lysosomes
TAMRA–penetratin demonstrated only a modest degree of lysosomal colocalization (47.3 ± 3.3%, mean + S.E.M.) after 30 min
In vitro
CCCCCCCC
Evidence 7 Activity

Activity

Cell-penetrating Peptides

Target

Sk-Br-3, Jimt-1, A431, Jurkat-Cells

Assay & Model

Athymic BALB/c nude mice xenografted A431tumors
Athymic BALB/c nude mice xenografted A431tumors

Source & Reference

CPPsite3.0
CPPsite3
EP2928502B1

Other

Natural residues Tetramer L Amphipathic
Protein derived
Anti-EGFR mAb matuzumab (Mat) , mAb trastuzumab (Her) and ADC adotrastuzumab-emtansine (Kad)
Vesicles
Lower internalization efficiency with values of 32%
Endocytosis
In vitro and in vivo
CCHHHHHHHHHSSCSCC
Evidence 8 Activity

Activity

Cell-penetrating Peptides

Assay & Model

Balb/c female mice (H-2d haplotype) of 8 to 12 weeks
Balb/c female mice (H-2d haplotype) of 8 to 12 weeks

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L Amphipathic
Protein derived
Recombinant hepatitis B surface protein (HBsAg)
Cytoplasm and Endosomes
Superior IgG response than TAT
Endocytosis
In vivo
CCCCCSCCCCSSSSCC
Evidence 9 Activity

Activity

Cell-penetrating Peptides

Target

SKBR-3 and MDA-MB-231 cells

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L Cationic
Protein derived
AFDye532 dye and naphthofluorescein (NF)
Cytosol
Endocytosis
In vitro
CCCCCCTTHHHHHHHHCC
Evidence 10 Activity

Activity

Cell-penetrating Peptides

Target

EBC-1 human squamous cell carcinoma

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L Amphipathic
Protein derived
5(6)-carboxyfluorescein (Cf) dye and Isoniazid (INH)
Cytoplasm, Nucleus and Lysosomes
Both showed similar internalization potency
In vitro
CCCCCCCCCCCCC
Additional Detail Fields 1 fields
CCCSSSTTCCCTTTTC CCCCCCCCCCCCSCC CCCCCCCC CCHHHHHHHHHSSCSCC CCCCCSCCCCSSSSCC CCCCCCTTHHHHHHHHCC CCCCCCCCCCCCC